Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Lujun Zhao
Risk-adapted use of thoracic radiotherapy in stage IV non-small cell lung cancer: a multicenter prognostic model study
Abstract Background: Survival benefit of thoracic radiotherapy (TRT) in patients with stage IV non-small cell lung cancer (NSCLC) receiving first-line chemo-immunotherapy remains uncertain. This study developed and validated an overall survival (OS) prediction model and assessed whether TRT benefit varied across risk strata. Methods: Patients with stage IV NSCLC treated with first-line chemo-immunotherapy were enrolled.
A prospective multicenter trial of deep learning auto-segmentation for organs at risk in thoracic radiotherapy
|
Abstract Widespread clinical implementation of rapidly evolving auto-segmentation tools remains constrained by a scarcity of high-quality prospective evidence. Here we show the results of a prospective, multicenter, observational trial (NCT05787522) evaluating the clinical performance of a deep learning model (iCurveE) for artificial intelligence (AI)-assisted delineation of organs at risk (OARs) in thoracic and breast cancer radiotherapy.
By Gengmin Niu, Yong Guan, Yifan Zhang, Yongchun Song, Songfeng Li, Tao Liu, Sheng Huang, Jingru Chen, Xiaofeng Wang, Wencheng Zhang, Junjie Chen, Jing Huang, Kunyu Yang, Jianzhong Cao, Hongqin Yuan, Xiaofeng Pei, Dongmei Wu, Yang Nan, Yao Lu, Lujun Zhao, Zhiyong Yuan, Maobin Meng, Yeman Liu, Yintao Fu, Donghe Zhao, Shuanshuan Guo, Ziye Yan
|
Nature
Verified
Induction and concurrent aumolertinib with radiotherapy for EGFR -mutated stage III NSCLC: results of phase III ADVANCE trial and real-world validation
Abstract The phase III ADVANCE study prospectively assessed a chemotherapy-free strategy combining aumolertinib with definitive radiotherapy (RT) in patients with unresectable stage III non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations (ChiCTR.org: ChiCTR2000040590). Participants were assigned in a 1:1 ratio to either the experimental arm (110 mg daily aulomertinib plus RT) or the control arm (cisplatin/pemetrexed with RT).
Donafenib combined with TACE to treat advanced HCC
Back to Journals » Journal of Hepatocellular Carcinoma » Volume 11 Authors Li J, Li Y, Song J, Zhao L Received 7 May 2024 Accepted for publication 21 June 2024 Published 27 June 2024 Volume 2024:11 Pages 1207—1219 DOI https://doi.org/10.2147/JHC.S473617 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Prof.
Effectiveness of CT radiomic features combined with clinical factors in predicting prognosis in patients with limited-stage small cell lung cancer - BMC Cancer
This study retrospectively identified patients with LS-SCLC admitted to Tianjin Medical University Cancer Institute and Hospital between September 2013 and March 2021. The Ethic Committee of Tianjin Medical University Cancer Institute and Hospital approved this study. Informed consent was obtained from all study participants.
Somatic mutations in DCC are associated with genomic instability and favourable outcomes in melanoma patients treated with immune checkpoint inhibitors | British Journal of Cancer
Abstract Background Deleted in colorectal cancer (DCC) encodes a transmembrane dependence receptor and is frequently mutated in melanoma. The associations of DCC mutation with chromosomal instability and immunotherapeutic efficacy in melanoma are largely uncharacterised.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Lujun
Contact Lujun, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack